Company intelligence / Profile preview
Transcenta
Hangzhou, Chinatranscenta.com ↗
- Ownership
- Public · 06628
- Employees
- ~88
- Development stage
- Phase 3
01
Overview
Transcenta has a broad pipeline of over ten biologic programs focused on oncology and selected non-oncology indications such as bone and kidney diseases. Its lead program Osemitamab (TST001), targeting CLDN18.2 for gastric/gastroesophageal cancer, has reached global Phase III pivotal trials in combination with Nivolumab and chemotherapy. The company collaborates with Agilent Technologies for companion diagnostics development.[3][7] Other programs are at various clinical stages.
- Therapeutic areas
- OncologyNephrologyRheumatology
- Modalities
- Monoclonal antibodies (mAbs)Antibody-based biotherapeutics[1][2][3][5][6]
- Industry
- Biotech
02
Drug pipeline
21 assets20 more assets in the full pipeline.
03
Partnerships
Agilent Technologies (companion diagnostic collaboration for CLDN18.2/Osemitamab)[7]
04
Financials
- Market cap
- $40.9M
- Total revenue
- $1.1M
- Enterprise value
- $61M
Beyond the preview
Go deeper on Transcenta.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcenta.